Last reviewed · How we verify
Sativex Medium Dose
At a glance
| Generic name | Sativex Medium Dose |
|---|---|
| Also known as | GW-1000-02 |
| Sponsor | GW Pharmaceuticals Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Repeated CBD Administration and Cannabis Outcomes (EARLY_PHASE1)
- A Study Testing the Effects of Different THC Doses on Psychological and Biological Function (PHASE1)
- Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration (PHASE2)
- Cannabis Edibles and Simulated Driving (NA)
- Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans (PHASE1)
- Use of a Cannabinoids as a Treatment Strategy for Alzheimer's Disease (PHASE2)
- Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy (PHASE2)
- Is Medicinal Cannabis an Effective Treatment for Tourette Syndrome in Adolescents? a Pilot Study (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sativex Medium Dose CI brief — competitive landscape report
- Sativex Medium Dose updates RSS · CI watch RSS
- GW Pharmaceuticals Ltd portfolio CI